Overview
This research investigates how the duration of a patient's initial response to first-line immunotherapy combined with platinum-based chemotherapy affects their survival when subsequently treated with non-immunotherapy, non-platinum chemotherapy regimens for advanced or metastatic non-small cell lung cancer (a/mNSCLC). The study used two large real-world datasets, ConcertAI Patient360™ NSCLC and the Flatiron Health Research Database, to analyze patient outcomes.
The key finding was that patients who maintained a response to their first-line treatment for more than six months experienced better overall survival when moving to subsequent non-immunotherapy, non-platinum-based chemotherapy regimens. This association held true regardless of how well their cancer initially responded to the first-line combination therapy.
Why this matters
After progression on first-line platinum and immunotherapy, patients with a/mNSCLC often transition to later-line non-immunotherapy, non-platinum chemotherapy in routine practice and the clinical outcomes can be highly variable. This study helps fill that gap by showing that the durability of benefit from first-line treatment carries meaningful prognostic information beyond response category alone. In practice, this can support clearer expectation-setting and risk stratification once patients move to later-line therapy, and it reinforces the need for first-line strategies that extend durable response and delay the development of resistance.